Mangafodipir is an organ-specific paramagnetic contrast agent indicated for the imaging of the hepatobiliary system and detecting lesions in the liver and pancreas. Mangafodipir is a contrast agent used as a diagnostic tool administered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver and pancreas.
- Mechanism
- Curator reviewed · 3 references
After intravenous administration, the chelate dissociates slowly to manganese and organic ligand fodipir (dipyridoxyl diphosphate), and manganese is taken up by the hepatocytes with high affinity and selectivity. The ligand fodipir is distributed to the extracellular fluid and later eliminated via urine. Mangafodipir shortens the longitudinal relaxation time (T1) of targeted tissues during MRI, where signal intensity or brightness is increased in normal liver parenchyma. Overall, there is increased contrast between normal tissue and abnormal tissue with lesions because there is a difference between cellular compositions, and manganese uptake in metastatic tissue or focal lesions is minimal or nearly absent.
- Primary indication
- Indicated for use as an organ-specific paramagnetic contrast agent developed for imaging of the hepatobiliary system and detecting lesions in liver and pancreas.Curator reviewed · 1 structured indication
- Formula / weight
- C22H30MnN4O14P2 · 691.382 g/mol (avg)
- First approval
- Canada, 2006
Resolves to
CXFKOLCMCRBYPL-UHFFFAOYSA-LSMILES[Mn++].CC1=C(O)C(CN(CCN(CC([O-])=O)CC2=CC(COP(O)(O)=O)=NC(C)=C2O)CC([O-])=O)=CC(COP(O)(O)=O)=N1What you can answer from here — as of August 30, 2026
Which other approved drugs treat the same conditions as Mangafodipir, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account